The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology

European Journal of Cancer

Volumn 51, Issue 18, 2015, Pages 2732-2739

  Barton, Sarah ^a   Peckitt, Clare ^a   Sclafani, Francesco ^a   Cunningham, David ^a   Chau, Ian ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Gastrointestinal cancer; Industry sponsorship; Randomised controlled trial; Subgroup analysis

Indexed keywords

ARTICLE; CANCER PATIENT; CLINICAL DECISION MAKING; DIGESTIVE SYSTEM CANCER; DRUG INDUSTRY; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; SAMPLE SIZE; SUBGROUP ANALYSIS; SYSTEMATIC REVIEW; ECONOMICS; FINANCIAL MANAGEMENT; GASTROENTEROLOGY; GASTROINTESTINAL NEOPLASMS; METHODOLOGY; ONCOLOGY; PATHOLOGY; PROCEDURES; RESEARCH; STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE III AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG INDUSTRY; GASTROENTEROLOGY; GASTROINTESTINAL NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESEARCH REPORT; RESEARCH SUPPORT AS TOPIC; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84959562615     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.08.030     Document Type: Article

References (10)

1. X. Sun, M. Briel, S.D. Walter, and G.H. Guyatt Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses BMJ 340 2010 c117
2. X. Sun, M. Briel, J.W. Busse, J.J. You, E.A. Akl, F. Mejza, and et al. The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review BMJ 342 2011 d1569
3. J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, and et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 5 2015 E359 E386
4. Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki, and et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 9742 2010 687 697
5. National Institute for Health and Care Excellence Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208) 2010 London; 2010
6. R. Wang, S.W. Lagakos, J.H. Ware, D.J. Hunter, and J.M. Drazen Statistics in medicine-reporting of subgroup analyses in clinical trials N Engl J Med 357 21 2007 2189 2194
7. X. Sun, M. Briel, J.W. Busse, J.J. You, E.A. Akl, F. Mejza, and et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review BMJ 344 2012 e1553
8. B. Kasenda, S. Schandelmaier, X. Sun, E. von Elm, J. You, A. Blumle, and et al. Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications BMJ 349 2014 g4539
9. S. Zhang, F. Liang, W. Li, and X. Hu Subgroup analyses in reporting of phase III clinical trials in solid tumors J Clin Oncol 33 15 2015 1697 1702
10. E.H. Turner, A.M. Matthews, E. Linardatos, R.A. Tell, and R. Rosenthal Selective publication of antidepressant trials and its influence on apparent efficacy N Engl J Med 358 3 2008 252 260